IFP Advisors’s PharmaCyte Biotech PMCB Stock Holding History

IFP Advisors’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$1	–	5125
2025 Q4	$1	Hold	1	–	–	﹤0.01%	4878
2025 Q3	$1	Hold	1	–	–	﹤0.01%	4829
2025 Q2	$1	Hold	1	–	–	﹤0.01%	4907
2025 Q1	$1	Buy	+1	New	+$2	﹤0.01%	4294

Other funds holding PMCB

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

IFP Advisors's PMCB Position: Q1 2026 in Review

IFP Advisors sold out of PharmaCyte Biotech (PMCB) in Q1 2026, closing a stake of 1 share — an estimated $1 sold.

IFP Advisors first reported a position in PMCB in Q1 2025 and held it in 4 quarters. The position peaked at $1 in Q4 2025. 32 funds tracked by Wall St. Rank hold PMCB as of Q1 2026.

IFP Advisors reported no remaining PharmaCyte Biotech position as of Q1 2026 after selling out during the quarter.
IFP Advisors sold 1 PharmaCyte Biotech share in Q1 2026, an estimated $1.
IFP Advisors first reported a position in PharmaCyte Biotech in Q1 2025 and held it in 4 quarters.
IFP Advisors's PharmaCyte Biotech position peaked at $1 in Q4 2025.
32 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2026.

Based on IFP Advisors's 13F filing for Q1 2026, filed 13 Apr 2026.